While removal of the biologics exclusivity provision from the United States-Mexico-Canada Agreement (USMCA) was the most significant change to the trade pact for the biopharma industry, there were several other revisions that may allow speedier entry of generic drugs.
The intellectual property rights chapter of the revised trade deal worked out between House Democrats and the Trump Administration...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?